InvestorNewsBreaks – PetVivo Holdings Inc. (NASDAQ: PETV) Applies for Dual Listing on Upstream

PetVivo Holdings (NASDAQ: PETV, PETVW), an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals, recently announced that it has begun the application process to dual list its shares on Upstream, the revolutionary trading app for digital securities and NFTs powered by Horizon Fintex and MERJ Exchange Limited. According to the announcement, the planned dual listing is designed to provide the company with access to a global, digital-first investor base that can trade using USDC digital currency along with credit, debit, PayPal and USD, unlocking liquidity and enhancing price discovery while globalizing the opportunity to invest in NASDAQ-listed PetVivo. “We are always looking for ways to provide greater liquidity and value to our shareholders,” said PetVivo CEO John Lai. “We see a dual listing on Upstream as being an excellent way to reach a worldwide market of potential new investors who can learn about our company.”

To view the full press release, visit https://ibn.fm/CJ8eS

About PetVivo Holdings Inc.

PetVivo Holdings is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The company’s strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics. PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of nineteen patents protects the company’s biomaterials, products, production processes and methods of use. The company’s lead product SPRYNG(TM) with OsteoCushion(TM) technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in dogs and horses, is currently available for commercial sale. For more information about PetVivo and its revolutionary product, please contact info1@PetVivo.com or visit www.PetVivo.com.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.